Skip to main content

Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Publication ,  Other
Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA
April 2, 2026

<p>Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia were monitored by InAlyzer system overtime after drug treatment. D. Micro-CT analysis of tibia microarchitecture after at the end of study (12 weeks of drug treatment). E & F. BMD measured by micro-CT in femur and tibia. G. The ratio of uterine wet weight to body weight post-mortem. Statistical significance was evaluated by 2-Way ANOVA, *P < 0.05 compared with sham vehicle. #P < 0.05, ##P < 0.01, compared with OVX-vehicle. Sham, surgery control; OVX, Bilateral ovariectomy</p>

Duke Scholars

DOI

Publication Date

April 2, 2026
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923580
Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923580.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

DOI

Publication Date

April 2, 2026